ASTS
AST SpaceMobile, Inc.
ASTS has the edge over BLSH overall, supported by stronger fundamentals and stronger modeled upside.
BLSH
Bullish
BLSH has lower modeled downside risk, despite its lower overall score.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
BLSH Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Stable | |
| Under pressure |
BLSH's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
BLSH PE Valuation
BLSH has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
BLSH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BLSH, with profitability improving. However, they disagree widely on these estimates.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the edge over BLSH in the latest year-over-year earnings comparison.
BLSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | — |
| Q2 2026 | -$9.12 | -$8.12 |
| Q1 2026 | -$6.60 | -$4.07 |
| Q4 2025 | -$5.10 | -1062% |
BLSH lost $9.12 per share over the past year, and its loss has widened in each of the last three quarters.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over BLSH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
BLSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $92.6M | -100% |
| Q1 2026 | $51.8B | -35% |
| Q4 2025 | $64.4B | -2.5% |
| Q3 2025 | $41.6B | -23% |
| Q2 2025 | $58.7B | +18% |
| Q1 2025 | $80.3B | -0.2% |
BLSH's revenue has slid since its 2024 peak: $93M last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 6.6% | +6.6 points |
| Q1 2026 | -0.1% | -0.1 points |
| Q4 2025 | 0% | 0 points |
| Q3 2025 | 0.1% | +0.1 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | 0% | 0 points |
| Q4 2024 | 0% | N/A |
| Q3 2024 | 0% | N/A |
BLSH has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
BLSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.1M | -88% |
| Q1 2026 | $89.6M | +$134.9M |
| Q4 2025 | $54.1M | +52% |
| Q3 2025 | -$48.7M | -$38.8M |
| Q2 2025 | $16.8M | +25% |
| Q1 2025 | -$45.3M | +$27.4M |
BLSH has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
BLSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +270K shares |
| 1 year | +3.6% | +5.2M shares |
BLSH has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BLSH hasn't bought back shares in the past year.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BLSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | 3.9x | Elevated |
BLSH's net debt is about 3.9 years of its operating earnings (EBITDA).
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
BLSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.1 | Neutral |
| Stochastic | 12.1 | Oversold |
BLSH's weekly RSI is 39 (neutral) and its Stochastic is 12 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
BLSH PE vs Technology Sector
BLSH has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has stronger trend alignment. ASTS is above 1 of 5 weekly averages versus BLSH above 0 of 3.
BLSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 20% below |
| 20 week MA | $28.5 | 19% below |
| 50 week MA | $32.8 | 29% below |
BLSH is in a downtrend: it's below all three of its weekly moving averages, and 29% below its 50-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
BLSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $69.5 | $41.1 | -41% |
| 2026 YTD | $41.1 | $23.2 | -44% |
BLSH has the edge over ASTS on returns for 2026, with the stronger performance.